Qian Cao

Appearances

RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Date
May 20, 2024
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
Presenter
Marla Dubinsky
Icahn School of Medicine, Mount Sinai
Speakers
Marc Ferrante
Raja Atreya
Bincy Abraham
Houston Methodist Hospital
Alessandro Armuzzi
Laurent Peyrin-Biroulet
Peter Bossuyt
Miguel Regueiro
Cleveland Clinic
Stefan Schreiber
Remo Panaccione
Krisztina Gecse
Qian Cao
Ezequiel Neimark
Toni Anschutz
Stijn van Haaren
Daniel O’Brien
Geert D’Haens